Over the past decade, several inhibitors of key metabolic dependencies have been shown to be active in AML (Acute Myeloid Leukemia), suggesting that targeting cellular metabolism is a promising therapeutic strategy for this disease. Specific inhibitors of the TCA cycle isoenzymes IDH1 and 2, mutated in approximately 20% of AML cases, abrogate the myeloid differentiation block and restore normal granulocytic/neutrophilic differentiation of IDH1/2-mutated AML blasts [1, 2] . Moreover, lonidamine and 2-deoxy-D-glucose, two small molecules that inhibit the first rate-limiting step of glycolysis, have been demonstated to have potent anti-leukemic activities in AML cells in preclinial studies and are now being tested in early phase clinical trials [3, 4] . While the inhibition of metabolic enzymes alters metabolite steady-state levels, it also impacts the activity of other downstream signaling pathways. For instance, glycolysis inhibition by lonidamine is associated with activation of the MEK/ERK pathway, which in the context of AML, could counteract the anti-leukemic effect of glycolysis inhibition [3] . This example suggests that it is essential to identify both the favorable effects and the potential liabilities of metabolic perturbations on downstream signaling pathways in order to (i) prevent potential resistance mechanisms to inhibition of the metabolic targets and (ii) nominate combination therapies that may synergize with metabolic inhibitors.
Over the past decade, several inhibitors of key metabolic dependencies have been shown to be active in AML (Acute Myeloid Leukemia), suggesting that targeting cellular metabolism is a promising therapeutic strategy for this disease. Specific inhibitors of the TCA cycle isoenzymes IDH1 and 2, mutated in approximately 20% of AML cases, abrogate the myeloid differentiation block and restore normal granulocytic/neutrophilic differentiation of IDH1/2-mutated AML blasts [1, 2] . Moreover, lonidamine and 2-deoxy-D-glucose, two small molecules that inhibit the first rate-limiting step of glycolysis, have been demonstated to have potent anti-leukemic activities in AML cells in preclinial studies and are now being tested in early phase clinical trials [3, 4] . While the inhibition of metabolic enzymes alters metabolite steady-state levels, it also impacts the activity of other downstream signaling pathways. For instance, glycolysis inhibition by lonidamine is associated with activation of the MEK/ERK pathway, which in the context of AML, could counteract the anti-leukemic effect of glycolysis inhibition [3] . This example suggests that it is essential to identify both the favorable effects and the potential liabilities of metabolic perturbations on downstream signaling pathways in order to (i) prevent potential resistance mechanisms to inhibition of the metabolic targets and (ii) nominate combination therapies that may synergize with metabolic inhibitors. We recently identified the mitochondrial creatine kinase, CKMT1, involved in arginine-creatine metabolism, as a new metabolic vulnerability in the molecular subset of AML driven by the proto-oncogene EVI1 [5] . We determined that suppression of arginine-creatine metabolism by CKMT1-directed shRNAs or by the small molecule cyclocreatine selectively altered the mitochondrial respiration and ATP production of EVI1-positive AML cells, thereby reducing their growth. In an effort to identify relevant signaling pathways that may be dysregulated by alteration of arginine-creatine metabolism, we interrogated by Gene Set Enrichment Analysis (GSEA) our transcriptional data generated through RNA-sequencing in three EVI1-positive AML cell lines, TF-1, UT-7, and UCSD-AML1, treated for 24 h with cyclocreatine (GSE86151). This open-ended enrichment analysis revealed that gene sets related to the GSK3 and WNT pathways were among those most enriched in genes whose expression was suppressed by cyclocreatine (Fig. 1a, b , odds ratio = 4.10, P value = 0.017; odds ratio = 10.24, P value = 0.004 for WNT and GSK3 respectively, based on two-tailed Fisher exact test). Creatine kinase (CK) pathway inhibition impaired the expression of both GSK3-target genes and protein members of WNT signaling from the most upstream genes involved in the pathway, such as WNT10b, WNT11, DVL2, FZD4, FZD6, and FZD7, to the most downstream targets, such as CTNNB1 and its well-reported targets MYC and CCND1 (Fig. 1c, d ).
Next, we performed single-sample Gene Set Enrichment Analysis (ssGSEA) in two large human primary patient AML gene expression datasets Wouters et al. (n = 526, GSE14468) and Tomasson et al. (n = 304, GSE10358). In both datasets, a significant correlation was observed between the transcriptional signatures of GSK3 inhibition and CK pathway inhibition (Fig. 1e , f and S1A). In line with these results, the level of GSK3 phosphorylation at the inhibitory serine sites of the two GSK3 isoforms (S21 on GSK3A and S9 on GSK3B) was strongly enhanced upon cyclocreatine treatment, confirming the inhibition of GSK3 in EVI1-positive AML cell lines and primary patient samples (Fig. 1g, h ). Interestingly, the basal level of S21/S9 GSK3 phosphorylation was higher in Kasumi-3, compared to the other EVI1-positive cell lines, suggesting less constitutive activation of GSK3 at baseline. Despite this high basal level of phosphorylation, GSK3 was further phosphorylated upon cyclocreatine treatment in Kasumi-3. Intracellular glycogen accumulation, which was previously reported as a direct phenotypic consequence of GSK3 inhibition [6] , was also observed both by Periodic AcidSchiff positive staining and glycogen dosage in cyclocreatine-treated AML cell lines and primary patient samples (Figs. S1C, 1I and 1J). Moreover, we previously reported that cyclocreatine treatment induced cell cycle arrest in AML cells [5] , and the cyclin-dependent kinase inhibitor p27Kip1 is a critical downstream mediator of the cell cycle arrest associated with GSK3 inhibition [7] . Consistent with these reports, cyclocreatine treatment increased p27Kip1 levels in the EVI1-positive AML cell line TF-1 ( Figure S1D ).
We recently reported that the reduced growth of EVI1-positive AML cell lines treated with cyclocreatine was associated with a decreased expression of the immature cell surface marker CD117 [5] . We also compared the effect of CK pathway inhibition on two mouse models, one which develop an Nras G12D + Evi1-driven AML that contains a clonal Evi1 integration and expresses high transcript levels of Evi1 and a second AML expressing an Nras G12D that does not express Evi1. We established that the Nras G12D + Evi1-driven disease burden was selectively altered by CK pathway inhibition [5] . To investigate whether inhibition of GSK3 signaling was important for such effects, we generated constitutively active GSK3 mutants by substituting serines 21 and 9 with non-phosphorylable alanines (S21A and S9A) on GSK3A and GSK3B, respectively (Fig. 2a) . Co-expression of GSK3A/B active mutants (S21A/S9A) in AML cells significantly attenuated the CD117 marker repression induced by cyclocreatine and CKMT1 knockdown ( Fig. 2b-d) . In addition, overexpression of Gsk3b S9A in Nras G12D + Evi1 cells significantly attenuated the anti-leukemic effect of cyclocreatine and reduced survival of the Gsk3b S9A subgroup compared to the wild-type (WT) Gsk3b subgroup (Fig. 2e, f) . Taken together, these results showed that GSK3 plays a substantial role in the cellular effects induced by CK pathway inhibition.
We and others have previously identified GSK3 as a target in hematopoietic cells transformed by HOX genes, and chemical inhibition or shRNA-targeting of either GSK3A selectively, or both GSK3A and GSK3B, were shown to impair AML cell viability and promote in vitro granulo-monocytic differentiation [8] [9] [10] [11] . While targeting GSK3 seems to be an interesting alternative in AML, all of these studies also raised an important question concerning the feasibility of such a therapeutic intervention given the role of GSK3 in WNT pathway regulation and HSC homeostasis [12] . Indeed, decreased expression or activity of GSK3 in the bone marrow promotes the expansion of HSCs through stabilization of CTNNB1 and a WNTdependent activation of stem cell self-renewal [13, 14] . Interestingly, in addition to its inhibitory effect on GSK3, cyclocreatine treatment also repressed the mRNA and protein levels of CTNNB1 (Fig. 2g-i) , and this effect was counteracted by reactivation of arginine-creatine metabolism upon phospho-creatine supplementation (Fig. 2i) . The GSK3 inhibitor, CHIR 99-021, was used as a positive control for CTNNB1 accumulation (Fig. 2i) . Despite GSK3 pathway inhibition, cyclocreatine treatment prevented nuclear CTNNB1 accumulation in TF-1 and UCSD-AML1 cells and thereby did not activate a TCF/LEF-GFP reporter 304, GSE10358 ). Data are presented as heatmaps. Depleted and enriched genes are respectively in blue and red. *P value reporting the overlap between GSK3 and creatine kinase pathways inhibition signatures was calculated using a two-tailed Fisher exact test. g Western immunoblot for p-GSK3A (S21), p-GSK3B (S9), GSK3A, GSK3B, and HSP90 after cyclocreatine treatment. h Western immunoblot for p-GSK3A (S21), p-GSK3B (S9), GSK3A, GSK3B, and VINCULIN after cyclocreatine treatment of three EVI1-positive primary AML patient samples. i, j Glycogen quantification after cyclocreatine treatment. *P value < 0.05 calculated using a Welch's t-test in comparison with the control condition. Error bars represent mean ± SEM of three to four replicates G12D + Evi1 and either wild-type (WT) or Gsk3b S9A mice (n = 7 for cyclocreatinetreated groups vs. n = 5 for vehicle-treated groups). Statistical significance determined by log-rank (Mantel-Cox) test. e, f *P value < 0.05 by comparison with the corresponding vehicle-treated group (Gsk3b WT or Gsk3b S9A). #P value < 0.05 by comparison with cyclocreatinetreated Gsk3b WT group. Ccr cyclocreatine. g, h mRNA level of expression of CTNNB1 after cyclocreatine (Ccr) treatment in AML cell lines (g) and primary patient samples (h). *P value < 0.05 calculated using a Mann-Whitney test in comparison with the control condition. Error bars represent mean ± SEM of four replicates. i Western immunoblot for p-GSK3A (S21), p-GSK3B (S9), GSK3A, GSK3B and CTNNB1 after cyclocreatine (Ccr), phosphocreatine (Phospho-Cr) and CHIR 99-021 (CHIR) treatment in UCSD-AML1 cells. j CTNNB1 immunofluorescence staining after cyclocreatine (Ccr) and CHIR 99-021 (CHIR) treatment (CTNNB1 in red and DAPI in blue). k Representative FACS analysis of a CTNNB1 TCF/LEF GFP reporter assay in response to cyclocreatine (Ccr) and CHIR 99-021 (CHIR) treatment. Colored number is percentage of positive cells system. In contrast, CHIR 99-021 stabilized CTNNB1 (Fig. 2j, k) .
Taken together, these results demonstrate that the blockade of the creatine pathway inhibits GSK3 and silences WNT pathway, thus impeding the canonical control of GSK3 on the WNT pathway through CTNNB1. By turning off WNT signaling, most likely through transcriptional downregulation of the entire pathway-including FZD4, FZD6, and CTNNB1 itself-CK pathway inhibition allows the anti-leukemic and pro-maturation effects of GSK3 inhibition without activation of the pro-leukemogenic WNT signaling pathway.
